A Clinical Trials Whistleblower at Novartis?

July 12, 2007
Peter Rost has been checking the Cafe Pharma boards, and noticed this thread concerning an employee wrongful termination suit.  The plaintiff is allegedly David Olagunju, who is said to have alleged that he was terminated for "refusing to alter safety data from the clinical trials for the cancer drug Tasigna and for objecting to exaggerated reports on the drug. "  If he is the David Olagunju that I think he is, he was Global Director of Statistical Reporting and Standards at Novartis and had chaired a session at the DIA conference last year.   Couldn't confirm anything about the case but it will be something to monitor. -AMS
Peter Rost has been checking the Cafe Pharma boards, and noticed this thread concerning an employee wrongful termination suit.  The plaintiff is allegedly David Olagunju, who is said to have alleged that he was terminated for "refusing to alter safety data from the clinical trials for the cancer drug Tasigna and for objecting to exaggerated reports on the drug. "  If he is the David Olagunju that I think he is, he was Global Director of Statistical Reporting and Standards at Novartis and had chaired a session at the DIA conference last year.   Couldn't confirm anything about the case but it will be something to monitor. -AMS
About the Author

pharmamanufacturing | pharmamanufacturing